(1 - 16 from 21
)
ESMO 2017: Rucaparib Shows Clinical Benefit as Maintenance ...
www.esmo.org
Jonathan Ledermann, Professor of Medical Oncology at UCL Cancer Institute and UCL Hospitals, London, UK presented findings from the double-blind, multinational phase III ARIEL3 trial (NCT ), which tested rucaparib as a maintenance therapy compared to placebo in women with high-grade ovarian, fallopian tube, or primary peritoneal cancer ...
Artios Pharma Announces Appointment of Dr. Ian PR Newswire UK
www.prnewswire.co.uk
Jonathan Ledermann is Professor of Medical Oncology in the UCL Cancer Institute and Director of Cancer Research UK and UCL Cancer ...
Clovis Oncology, Inc. - Clovis Oncology Presents Comprehensive...
ir.clovisoncology.com
... regardless of their tumor genetics,” said Professor Jonathan Ledermann , MD, Professor of Medical Oncology, Director, Cancer Research UK ...
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
www.globenewswire.com
... life,” said Jonathan Ledermann, Professor of Medical Oncology at the University College London Cancer Institute. “ZEJULA offers the chance ...
sorted by relevance / date